Glaukos Completes Enrollment in PRESERFLO MicroShunt Pivotal Study
Aliso Viejo, California, July 27, 2026 Glaukos Corporation announced the completion of patient enrollment in its U.S. 510(k) pivotal...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
Aliso Viejo, California, July 27, 2026 Glaukos Corporation announced the completion of patient enrollment in its U.S. 510(k) pivotal...
VAUGHAN, Ontario, May 7, 2026 Bausch + Lomb announced the European launch of its advanced Bi-Blade+â„¢ dual-port vitrectomy cutter...
CAMPBELL, CALIFORNIA | January 26, 2026 — Myra Vision, a Shifamed portfolio company, announced that the first patient has...
